The role of entecavir in preventing hepatitis B recurrence after liver transplantation

Journal of Digestive Diseases

Volumn 10, Issue 4, 2009, Pages 321-327

  Xi, Zhi Feng ^a   Xia, Qiang ^a   Zhang, Jian Jun ^a   Chen, Xiao Song ^a   Han, Long Zhi ^a   Wang, Xin ^a   Shen, Cong Huan ^a   Luo, Yi ^a   Xin, Tian Yu ^a   Wang, Si Yue ^b   Qiu, De Kai ^b  

^a Department of Organ Transplantation ^*  (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Entecavir; Hepatitis B immunoglobulin; Hepatitis B recurrence; Lamivudine; Liver transplantation

Indexed keywords

ANTIFUNGAL AGENT; CYCLOSPORIN A; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VIRUS DNA;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; SURVIVAL RATE;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIERS ESTIMATE; LAMIVUDINE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 70449105201     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2009.00403.x     Document Type: Article

References (19)

1. Schiff ER. Prevention of mortality from hepatitis B and hepatitis C. Lancet 2006, 368:896-7.
2. Gane EJ, Angus PW, Strasser S. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007, 132:931-7.
3. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004, 10:968-74.
4. Lok AS, Lai CL, Leung N. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714-22.
5. Olivera-Martinez MA, Gallegos-Orozco JF. Recurrent viral liver disease (hepatitis B and C) after liver transplantation. Arch Med Res 2007, 38:691-701.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ. Long-term therapy with adefovir dipivoxil for HBeaG-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743-51.
7. Lai CL, Gane E, Hsu CW. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) versus lamivudine. Presented at th 57th Annual Meeting of the American Association for the Study of Liver Diseases, 27-31 October 2006. Boston, MA, USA
8. Chang TT, Gish RG, De Mau R. AI463022 Behold Study Group. A comparison of entecavir and lamvudine for HBeaG-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-10.
9. Lai CL, Shouval D, Lok AS. AI463027 Behold Study Group. Entecavir versus lamivudine for patients with hbeag-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-20.
10. Tenney DJ, Pokorowski KA, Rose RE. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008, 2:A88-89. Abstract PL02
11. Shakil AO, Lilly L, Angus P. Entecavir significantly reduces viral load in liver transplant recipients failing lamvudine therapy for chronic hepatitis B infection. J Hepatol 2002, 36(1):122. Suppl., Abstract 433
12. Samuelson A, Morgan M, Reynolds J. The use of entecavir following liver transplantation: pilot safety and tolerability data. Am J Gastroenterol 2008, 103(1):S160. Suppl.
13. Merican I, Guan R, Amarapuka D. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000, 15:1356-61.
14. Leung N, Peng C-Y, Sollano J. Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeaG(+) antiviral-naive Adults: 24 wk results (E.A.R.L.Y. Study). Hepatology 2006, 44(4):554A. Suppl
15. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 2009, 50:227-42. European Association for the Study of the Liver
16. Liaw YF, Leung N, Kao JH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. The Asian-Pacific Association for the study of the liver. Hepatol Int 2008, 2:263-83.
17. Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008, 2:284-95.
18. Yuan Y, Iloeje U, Li H. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese social security program. ISPOR 2008, 2:S11-22.
19. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004, 10(2):S74. Suppl.